Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Место кандесартана в лечении артериальной гипертонии у коморбидных пациентов
Место кандесартана в лечении артериальной гипертонии у коморбидных пациентов
Бернс С.А., Стрюк Р.И. Место кандесартана в лечении артериальной гипертонии у коморбидных пациентов. Consilium Medicum. 2017; 19 (5): 14–19.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
К настоящему времени в условиях демографического старения населения отмечается рост числа заболеваний у одного пациента. Наболее часто встречается сочетание ишемической болезни сердца, артериальной гипертензии, хронической сердечной недостаточности, сахарного диабета и др. Все перечисленные заболевания участвуют в той или иной степени в сердечно-сосудистом континууме. Блокаторы рецепторов ангиотензина способны эффективно контролировать артериальное давление и обладают доказанными органопротективными эффектами. В статье представлен литературный обзор по применению кандесартана цилексетила у пациентов с артериальной гипертонией и коморбидной патологией. Обсуждаются особенности фармакокинетики и фарамакодинамики кандесартана. Представлена доказательная база его антигипертензивной эффективности и защиты органов-мишеней. Показана возможность использования генерика кандесартана (Гипосарт) с доказанной биоэквивалентностью оригинальному препарату.
Ключевые слова: ренин-ангиотензин-альдостероновая система, блокаторы рецепторов ангиотензина, артериальная гипертония, коморбидность, кандесартан.
Key words: the renin-angiotensin-aldosterone system, angiotensin receptor blockers, hypertension, comorbidity, candesartan.
Ключевые слова: ренин-ангиотензин-альдостероновая система, блокаторы рецепторов ангиотензина, артериальная гипертония, коморбидность, кандесартан.
________________________________________________
Key words: the renin-angiotensin-aldosterone system, angiotensin receptor blockers, hypertension, comorbidity, candesartan.
Полный текст
Список литературы
1. Статистическая служба Европейского союза (Евростат), доклад «О старении населения в Европе». Всемирная организация здравоохранения, 01.10.2015. / Statisticheskaia sluzhba Evropeiskogo soiuza (Evrostat), doklad «O starenii naseleniia v Evrope». Vsemirnaia organizatsiia zdravookhraneniia, 01.10.2015. [in Russian]
2. Верткин А.Л., Румянцев М.А., Скотников А.С. Коморбидность. Клин. медицина. 2012; 10: 4–11. / Vertkin A.L., Rumiantsev M.A., Skotnikov A.S. Komorbidnost'. Klin. meditsina. 2012; 10: 4–11. [in Russian]
3. Верткин А.Л., Скотников А.С. Лечащий врач. 2009; 4: 61–7. / Vertkin A.L., Skotnikov A.S. Lechashchii vrach. 2009; 4: 61–7. [in Russian]
4. Губанова Г.В., Беляева Ю.Н., Шеметова Г.Н. Коморбидный пациент: этапы формирования, факторы риска и тактика ведения. Совр. проблемы науки и образования. 2015; 6. / Gubanova G.V., Beliaeva Iu.N., Shemetova G.N. Komorbidnyi patsient: etapy formirovaniia, faktory riska i taktika vedeniia. Sovr. problemy nauki i obrazovaniia. 2015; 6. [in Russian]
5. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373–83.
6. Гиляревский С.Р. Современные возможности блокады ренин-ангиотензиновой системы: остаются ли ингибиторы ангиотензинпревращающего фермента препаратами первого ряда? Consilium Medicum. 2010; 12 (5): 18–23. / Giliarevskii S.R. Sovremennye vozmozhnosti blokady renin-angiotenzinovoi sistemy: ostaiutsia li ingibitory angiotenzinprevrashchaiushchego fermenta preparatami pervogo riada? Consilium Medicum. 2010; 12 (5): 18–23. [in Russian].
7. Mancia G, Fagard R, Narkiewicz K et al. Task Force Members. 2013 ESH 'ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7): 1281–357.
8. Барышникова Г.А. Сравнительный метаанализ эффективности сартанов при лечении артериальной гипертензии. РМЖ. Кардиология. 2010; 18 (22). / Baryshnikova G.A. Sravnitel'nyi meta-analiz effektivnosti sartanov pri lechenii arterial'noi gipertenzii. RMZh. Kardiologiia. 2010; 18 (22). [in Russian]
9. Hermida RC, Ayala DE, Vojon A et al. Influence of circadian time of hypertension treatment on cardiovascular risk: result of the MAPEC study. Chronobiol Int 2010; 27: 1629–51.
10. Сиренко Ю.Н., Донченко Н.В. Место кандесартана в современной терапии сердечно-сосудистых заболеваний: обзор доказательств. Артериальная гипертензия. 2011; 4 (18): 114–26. / Sirenko Iu.N., Donchenko N.V. Mesto kandesartana v sovremennoi terapii serdechno-sosudistykh zabolevanii: obzor dokazatel'stv. Arterial'naia gipertenziia. 2011; 4 (18): 114–26. [in Russian]
11. Захарова Н.В., Кузьмина-Крутецкая С.Р. Клиническая фармакология сартанов: класс-эффект и фармакодинамические особенности препаратов. Системные гипертензии. 2011; 7 (3): 12–7. / Zakharova N.V., Kuz'mina-Krutetskaia S.R. Klinicheskaia farmakologiia sartanov: klass-effekt i farmakodinamicheskie osobennosti preparatov. Systemic Hypertension. 2011; 7 (3): 12–7. [in Russian]
12. Морозова Т.Е. Сартаны в лечении больных артериальной гипертензией высокого риска: возможности кандесартана. Системные гипертензии. 2013; 9 (2): 34–9. / Morozova T.E. Sartany v lechenii bol'nykh arterial'noi gipertenziei vysokogo riska: vozmozhnosti kandesartana. Systemic Hypertension. 2013; 9 (2): 34–9. [in Russian]
13. Гиляревский С.Р., Голшмид М.В., Кузьмина И.М. Доказательная история кандесартана: прошлое, будущее и настоящее. Сердечная недостаточность. 2015; 16 (5): 303–10. / Giliarevskii S.R., Golshmid M.V., Kuz'mina I.M. Dokazatel'naia istoriia kandesartana: proshloe, budushchee i nastoiashchee. Serdechnaia nedostatochnost'. 2015; 16 (5): 303–10. [in Russian]
14. Oparll S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens 2000; 13 (1 Pt 2): 188–248.
15. Евдокимова А.Г., Ложкина М.В., Коваленко Е.В. Особенности применения кандесартана в клинической практике. Consilium Medicum. 2016; 18 (1): 54–9. / Evdokimova A.G., Lozhkina M.V., Kovalenko E.V. Key features of candesartan application in clinical practice. Consilium Medicum. 2016; 18 (1): 54–9. [in Russian]
16. Le MT, De Bakcer JP, Hanyady L et al. Ligand binding and functional properties of human angiotensin AT I receptors in transiently and stably expressed CHO-K1 cell. Eur J Pharmacol 2005; 513 (1–2): 35–45.
17. Остроумова О.Д., Бондарец О.В., Гусева Т.Ф. Преимущества кандесартана в лечении артериальной гипертонии. Системные гипертензии. 2014; 10 (2): 62–6. / Ostroumova O.D., Bondarets O.V., Guseva T.F. The benefits of candesartan usage in the treatment of arterial hypertension. Systemic Hypertension. 2014; 10 (2): 62–6. [in Russian]
18. Lee HY, Hong BK, Chung WJ et al. Phase IV, 8-week, multicenteral, randomized, active treatment-controlled, parallel grope, efficacy and tolerability of candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension. Clin Ther 2011; 33 (8): 1043–56.
19. Easthope SE, Jarvis B. Candesartan cilexetil in update of its use in essential hypertension. Drugs 2002; 62: 1253–87.
20. Vidi DG, While WB, Ridley E et al and the CLAIM Study Investigators. A forsed titration study of antihypertensive efficacy of candesartanin cilexetil in comparison to losartan. CLAIM Study II. J Hum Hypertens 2001; 15: 475–80.
21. Hasegawa H, Takano H, Kameda E et al. Effect of switching from telmisartan, valsartan, olmesartan or losartan, to candesartan on morning hypertension. Clin Exp Hypertens 2012; 34 (2): 86–91.
22. Minatoquchi S, Aoyama T, Kawai N et al. Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. Blood Press 2013; 22.
23. Ogihara T, Fujimoto A, Nakao K, Saruta T. CASE-J Trial Group. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Exp Rev Cardiovasc Ther 2008; 6 (9): 1195–201.
24. Ogihara T, Nakao K, Fukui T et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008; 51 (2): 393–8.
25. Penicka M, Gregor P, Kerekes R et al. Candesartan use in Hypertrophic And Non-obstructive Cardiomyopathy Estate (CHANCE) Study. The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. J Mol Diagn 2009; 11: 35–41.
26. Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363–9.
27. Kurata A, Nishizawa H, Kihara S et al. Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 2006; 70: 1717–24.
28. Rudziftski W, Swiat M, Tomaszewski M et al. Cerebral hemodynamics and investigations of cerebral blood flow regulation. Nucl Med Rev Cent East Eur 2007; 10: 29–42.
29. Lithell H, Hansson L, Skoog I et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–86.
30. Schrader J, Kulschewski A et al. Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34: 1699–703.
31. Kasanuki H, Hagiwara N, Hosoda S et al. Angiotensin II receptor blocker-based vs non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30 (10): 1203–12.
32. Burnier M. Managing 'resistance': is adherence a target for treatment? Curr Opin Nephrol Hypertens 2014; 23 (5): 439–43.
33. Fliser D, Wagner K, Loss A et al. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16: 1135–40.
34. De Rosa ML. Cardio classics revisited – focus on the role of candesartan. Vas Health Risk Management 2010; 6: 1047–63.
35. Pfeffer MA, Swedberg K, Granger CB et al. For the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759–66.
36. Granger CB, McMurray JJV, Yusuf S et al. For the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin converting enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772–6.
37. McMurray JJV, Оstergren J, Swedberg K et al. For the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin converting enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767–71.
38. Yusuf S, Pfeffer MA, Swedberg K et al for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777–81.
39. Чазова И.Е., Ратова Л.Г. Первое поколение сартанов: есть ли перспективы. Системные гипертензии. 2010; 4: 3–7. / Chazova I.E., Ratova L.G. Pervoe pokolenie sartanov: est' li perspektivy. Systemic Hypertension. 2010; 4: 3–7. [in Russian]
40. Ducharme A, Swedberg K, Pfeffer MA et al. CHARM Investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152: 86–92.
41. Добрынина Н.В. Что мы знаем о кандесартане: возможности клинического применения. Consilium Medicum. 2016; 18 (5): 64–6. / Dobrynina N.V. What we know about candesartan: clinical applications. Consilium Medicum. 2016; 18 (5): 64–6. [in Russian]
2. Vertkin A.L., Rumiantsev M.A., Skotnikov A.S. Komorbidnost'. Klin. meditsina. 2012; 10: 4–11. [in Russian]
3. Vertkin A.L., Skotnikov A.S. Lechashchii vrach. 2009; 4: 61–7. [in Russian]
4. Gubanova G.V., Beliaeva Iu.N., Shemetova G.N. Komorbidnyi patsient: etapy formirovaniia, faktory riska i taktika vedeniia. Sovr. problemy nauki i obrazovaniia. 2015; 6. [in Russian]
5. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373–83.
6. Giliarevskii S.R. Sovremennye vozmozhnosti blokady renin-angiotenzinovoi sistemy: ostaiutsia li ingibitory angiotenzinprevrashchaiushchego fermenta preparatami pervogo riada? Consilium Medicum. 2010; 12 (5): 18–23. [in Russian].
7. Mancia G, Fagard R, Narkiewicz K et al. Task Force Members. 2013 ESH 'ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7): 1281–357.
8. Baryshnikova G.A. Sravnitel'nyi meta-analiz effektivnosti sartanov pri lechenii arterial'noi gipertenzii. RMZh. Kardiologiia. 2010; 18 (22). [in Russian]
9. Hermida RC, Ayala DE, Vojon A et al. Influence of circadian time of hypertension treatment on cardiovascular risk: result of the MAPEC study. Chronobiol Int 2010; 27: 1629–51.
10. Sirenko Iu.N., Donchenko N.V. Mesto kandesartana v sovremennoi terapii serdechno-sosudistykh zabolevanii: obzor dokazatel'stv. Arterial'naia gipertenziia. 2011; 4 (18): 114–26. [in Russian]
11. Zakharova N.V., Kuz'mina-Krutetskaia S.R. Klinicheskaia farmakologiia sartanov: klass-effekt i farmakodinamicheskie osobennosti preparatov. Systemic Hypertension. 2011; 7 (3): 12–7. [in Russian]
12. Morozova T.E. Sartany v lechenii bol'nykh arterial'noi gipertenziei vysokogo riska: vozmozhnosti kandesartana. Systemic Hypertension. 2013; 9 (2): 34–9. [in Russian]
13. Giliarevskii S.R., Golshmid M.V., Kuz'mina I.M. Dokazatel'naia istoriia kandesartana: proshloe, budushchee i nastoiashchee. Serdechnaia nedostatochnost'. 2015; 16 (5): 303–10. [in Russian]
14. Oparll S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens 2000; 13 (1 Pt 2): 188–248.
15. Evdokimova A.G., Lozhkina M.V., Kovalenko E.V. Key features of candesartan application in clinical practice. Consilium Medicum. 2016; 18 (1): 54–9. [in Russian]
16. Le MT, De Bakcer JP, Hanyady L et al. Ligand binding and functional properties of human angiotensin AT I receptors in transiently and stably expressed CHO-K1 cell. Eur J Pharmacol 2005; 513 (1–2): 35–45.
17. Ostroumova O.D., Bondarets O.V., Guseva T.F. The benefits of candesartan usage in the treatment of arterial hypertension. Systemic Hypertension. 2014; 10 (2): 62–6. [in Russian]
18. Lee HY, Hong BK, Chung WJ et al. Phase IV, 8-week, multicenteral, randomized, active treatment-controlled, parallel grope, efficacy and tolerability of candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension. Clin Ther 2011; 33 (8): 1043–56.
19. Easthope SE, Jarvis B. Candesartan cilexetil in update of its use in essential hypertension. Drugs 2002; 62: 1253–87.
20. Vidi DG, While WB, Ridley E et al and the CLAIM Study Investigators. A forsed titration study of antihypertensive efficacy of candesartanin cilexetil in comparison to losartan. CLAIM Study II. J Hum Hypertens 2001; 15: 475–80.
21. Hasegawa H, Takano H, Kameda E et al. Effect of switching from telmisartan, valsartan, olmesartan or losartan, to candesartan on morning hypertension. Clin Exp Hypertens 2012; 34 (2): 86–91.
22. Minatoquchi S, Aoyama T, Kawai N et al. Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. Blood Press 2013; 22.
23. Ogihara T, Fujimoto A, Nakao K, Saruta T. CASE-J Trial Group. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Exp Rev Cardiovasc Ther 2008; 6 (9): 1195–201.
24. Ogihara T, Nakao K, Fukui T et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008; 51 (2): 393–8.
25. Penicka M, Gregor P, Kerekes R et al. Candesartan use in Hypertrophic And Non-obstructive Cardiomyopathy Estate (CHANCE) Study. The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. J Mol Diagn 2009; 11: 35–41.
26. Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363–9.
27. Kurata A, Nishizawa H, Kihara S et al. Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 2006; 70: 1717–24.
28. Rudziftski W, Swiat M, Tomaszewski M et al. Cerebral hemodynamics and investigations of cerebral blood flow regulation. Nucl Med Rev Cent East Eur 2007; 10: 29–42.
29. Lithell H, Hansson L, Skoog I et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–86.
30. Schrader J, Kulschewski A et al. Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34: 1699–703.
31. Kasanuki H, Hagiwara N, Hosoda S et al. Angiotensin II receptor blocker-based vs non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30 (10): 1203–12.
32. Burnier M. Managing 'resistance': is adherence a target for treatment? Curr Opin Nephrol Hypertens 2014; 23 (5): 439–43.
33. Fliser D, Wagner K, Loss A et al. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16: 1135–40.
34. De Rosa ML. Cardio classics revisited – focus on the role of candesartan. Vas Health Risk Management 2010; 6: 1047–63.
35. Pfeffer MA, Swedberg K, Granger CB et al. For the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759–66.
36. Granger CB, McMurray JJV, Yusuf S et al. For the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin converting enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772–6.
37. McMurray JJV, Оstergren J, Swedberg K et al. For the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin converting enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767–71.
38. Yusuf S, Pfeffer MA, Swedberg K et al for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777–81.
39. Chazova I.E., Ratova L.G. Pervoe pokolenie sartanov: est' li perspektivy. Systemic Hypertension. 2010; 4: 3–7. [in Russian]
40. Ducharme A, Swedberg K, Pfeffer MA et al. CHARM Investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152: 86–92.
41. Dobrynina N.V. What we know about candesartan: clinical applications. Consilium Medicum. 2016; 18 (5): 64–6. [in Russian]
2. Верткин А.Л., Румянцев М.А., Скотников А.С. Коморбидность. Клин. медицина. 2012; 10: 4–11. / Vertkin A.L., Rumiantsev M.A., Skotnikov A.S. Komorbidnost'. Klin. meditsina. 2012; 10: 4–11. [in Russian]
3. Верткин А.Л., Скотников А.С. Лечащий врач. 2009; 4: 61–7. / Vertkin A.L., Skotnikov A.S. Lechashchii vrach. 2009; 4: 61–7. [in Russian]
4. Губанова Г.В., Беляева Ю.Н., Шеметова Г.Н. Коморбидный пациент: этапы формирования, факторы риска и тактика ведения. Совр. проблемы науки и образования. 2015; 6. / Gubanova G.V., Beliaeva Iu.N., Shemetova G.N. Komorbidnyi patsient: etapy formirovaniia, faktory riska i taktika vedeniia. Sovr. problemy nauki i obrazovaniia. 2015; 6. [in Russian]
5. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373–83.
6. Гиляревский С.Р. Современные возможности блокады ренин-ангиотензиновой системы: остаются ли ингибиторы ангиотензинпревращающего фермента препаратами первого ряда? Consilium Medicum. 2010; 12 (5): 18–23. / Giliarevskii S.R. Sovremennye vozmozhnosti blokady renin-angiotenzinovoi sistemy: ostaiutsia li ingibitory angiotenzinprevrashchaiushchego fermenta preparatami pervogo riada? Consilium Medicum. 2010; 12 (5): 18–23. [in Russian].
7. Mancia G, Fagard R, Narkiewicz K et al. Task Force Members. 2013 ESH 'ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7): 1281–357.
8. Барышникова Г.А. Сравнительный метаанализ эффективности сартанов при лечении артериальной гипертензии. РМЖ. Кардиология. 2010; 18 (22). / Baryshnikova G.A. Sravnitel'nyi meta-analiz effektivnosti sartanov pri lechenii arterial'noi gipertenzii. RMZh. Kardiologiia. 2010; 18 (22). [in Russian]
9. Hermida RC, Ayala DE, Vojon A et al. Influence of circadian time of hypertension treatment on cardiovascular risk: result of the MAPEC study. Chronobiol Int 2010; 27: 1629–51.
10. Сиренко Ю.Н., Донченко Н.В. Место кандесартана в современной терапии сердечно-сосудистых заболеваний: обзор доказательств. Артериальная гипертензия. 2011; 4 (18): 114–26. / Sirenko Iu.N., Donchenko N.V. Mesto kandesartana v sovremennoi terapii serdechno-sosudistykh zabolevanii: obzor dokazatel'stv. Arterial'naia gipertenziia. 2011; 4 (18): 114–26. [in Russian]
11. Захарова Н.В., Кузьмина-Крутецкая С.Р. Клиническая фармакология сартанов: класс-эффект и фармакодинамические особенности препаратов. Системные гипертензии. 2011; 7 (3): 12–7. / Zakharova N.V., Kuz'mina-Krutetskaia S.R. Klinicheskaia farmakologiia sartanov: klass-effekt i farmakodinamicheskie osobennosti preparatov. Systemic Hypertension. 2011; 7 (3): 12–7. [in Russian]
12. Морозова Т.Е. Сартаны в лечении больных артериальной гипертензией высокого риска: возможности кандесартана. Системные гипертензии. 2013; 9 (2): 34–9. / Morozova T.E. Sartany v lechenii bol'nykh arterial'noi gipertenziei vysokogo riska: vozmozhnosti kandesartana. Systemic Hypertension. 2013; 9 (2): 34–9. [in Russian]
13. Гиляревский С.Р., Голшмид М.В., Кузьмина И.М. Доказательная история кандесартана: прошлое, будущее и настоящее. Сердечная недостаточность. 2015; 16 (5): 303–10. / Giliarevskii S.R., Golshmid M.V., Kuz'mina I.M. Dokazatel'naia istoriia kandesartana: proshloe, budushchee i nastoiashchee. Serdechnaia nedostatochnost'. 2015; 16 (5): 303–10. [in Russian]
14. Oparll S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens 2000; 13 (1 Pt 2): 188–248.
15. Евдокимова А.Г., Ложкина М.В., Коваленко Е.В. Особенности применения кандесартана в клинической практике. Consilium Medicum. 2016; 18 (1): 54–9. / Evdokimova A.G., Lozhkina M.V., Kovalenko E.V. Key features of candesartan application in clinical practice. Consilium Medicum. 2016; 18 (1): 54–9. [in Russian]
16. Le MT, De Bakcer JP, Hanyady L et al. Ligand binding and functional properties of human angiotensin AT I receptors in transiently and stably expressed CHO-K1 cell. Eur J Pharmacol 2005; 513 (1–2): 35–45.
17. Остроумова О.Д., Бондарец О.В., Гусева Т.Ф. Преимущества кандесартана в лечении артериальной гипертонии. Системные гипертензии. 2014; 10 (2): 62–6. / Ostroumova O.D., Bondarets O.V., Guseva T.F. The benefits of candesartan usage in the treatment of arterial hypertension. Systemic Hypertension. 2014; 10 (2): 62–6. [in Russian]
18. Lee HY, Hong BK, Chung WJ et al. Phase IV, 8-week, multicenteral, randomized, active treatment-controlled, parallel grope, efficacy and tolerability of candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension. Clin Ther 2011; 33 (8): 1043–56.
19. Easthope SE, Jarvis B. Candesartan cilexetil in update of its use in essential hypertension. Drugs 2002; 62: 1253–87.
20. Vidi DG, While WB, Ridley E et al and the CLAIM Study Investigators. A forsed titration study of antihypertensive efficacy of candesartanin cilexetil in comparison to losartan. CLAIM Study II. J Hum Hypertens 2001; 15: 475–80.
21. Hasegawa H, Takano H, Kameda E et al. Effect of switching from telmisartan, valsartan, olmesartan or losartan, to candesartan on morning hypertension. Clin Exp Hypertens 2012; 34 (2): 86–91.
22. Minatoquchi S, Aoyama T, Kawai N et al. Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. Blood Press 2013; 22.
23. Ogihara T, Fujimoto A, Nakao K, Saruta T. CASE-J Trial Group. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Exp Rev Cardiovasc Ther 2008; 6 (9): 1195–201.
24. Ogihara T, Nakao K, Fukui T et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008; 51 (2): 393–8.
25. Penicka M, Gregor P, Kerekes R et al. Candesartan use in Hypertrophic And Non-obstructive Cardiomyopathy Estate (CHANCE) Study. The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. J Mol Diagn 2009; 11: 35–41.
26. Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363–9.
27. Kurata A, Nishizawa H, Kihara S et al. Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 2006; 70: 1717–24.
28. Rudziftski W, Swiat M, Tomaszewski M et al. Cerebral hemodynamics and investigations of cerebral blood flow regulation. Nucl Med Rev Cent East Eur 2007; 10: 29–42.
29. Lithell H, Hansson L, Skoog I et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–86.
30. Schrader J, Kulschewski A et al. Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34: 1699–703.
31. Kasanuki H, Hagiwara N, Hosoda S et al. Angiotensin II receptor blocker-based vs non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30 (10): 1203–12.
32. Burnier M. Managing 'resistance': is adherence a target for treatment? Curr Opin Nephrol Hypertens 2014; 23 (5): 439–43.
33. Fliser D, Wagner K, Loss A et al. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16: 1135–40.
34. De Rosa ML. Cardio classics revisited – focus on the role of candesartan. Vas Health Risk Management 2010; 6: 1047–63.
35. Pfeffer MA, Swedberg K, Granger CB et al. For the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759–66.
36. Granger CB, McMurray JJV, Yusuf S et al. For the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin converting enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772–6.
37. McMurray JJV, Оstergren J, Swedberg K et al. For the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin converting enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767–71.
38. Yusuf S, Pfeffer MA, Swedberg K et al for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777–81.
39. Чазова И.Е., Ратова Л.Г. Первое поколение сартанов: есть ли перспективы. Системные гипертензии. 2010; 4: 3–7. / Chazova I.E., Ratova L.G. Pervoe pokolenie sartanov: est' li perspektivy. Systemic Hypertension. 2010; 4: 3–7. [in Russian]
40. Ducharme A, Swedberg K, Pfeffer MA et al. CHARM Investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152: 86–92.
41. Добрынина Н.В. Что мы знаем о кандесартане: возможности клинического применения. Consilium Medicum. 2016; 18 (5): 64–6. / Dobrynina N.V. What we know about candesartan: clinical applications. Consilium Medicum. 2016; 18 (5): 64–6. [in Russian]
________________________________________________
2. Vertkin A.L., Rumiantsev M.A., Skotnikov A.S. Komorbidnost'. Klin. meditsina. 2012; 10: 4–11. [in Russian]
3. Vertkin A.L., Skotnikov A.S. Lechashchii vrach. 2009; 4: 61–7. [in Russian]
4. Gubanova G.V., Beliaeva Iu.N., Shemetova G.N. Komorbidnyi patsient: etapy formirovaniia, faktory riska i taktika vedeniia. Sovr. problemy nauki i obrazovaniia. 2015; 6. [in Russian]
5. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373–83.
6. Giliarevskii S.R. Sovremennye vozmozhnosti blokady renin-angiotenzinovoi sistemy: ostaiutsia li ingibitory angiotenzinprevrashchaiushchego fermenta preparatami pervogo riada? Consilium Medicum. 2010; 12 (5): 18–23. [in Russian].
7. Mancia G, Fagard R, Narkiewicz K et al. Task Force Members. 2013 ESH 'ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7): 1281–357.
8. Baryshnikova G.A. Sravnitel'nyi meta-analiz effektivnosti sartanov pri lechenii arterial'noi gipertenzii. RMZh. Kardiologiia. 2010; 18 (22). [in Russian]
9. Hermida RC, Ayala DE, Vojon A et al. Influence of circadian time of hypertension treatment on cardiovascular risk: result of the MAPEC study. Chronobiol Int 2010; 27: 1629–51.
10. Sirenko Iu.N., Donchenko N.V. Mesto kandesartana v sovremennoi terapii serdechno-sosudistykh zabolevanii: obzor dokazatel'stv. Arterial'naia gipertenziia. 2011; 4 (18): 114–26. [in Russian]
11. Zakharova N.V., Kuz'mina-Krutetskaia S.R. Klinicheskaia farmakologiia sartanov: klass-effekt i farmakodinamicheskie osobennosti preparatov. Systemic Hypertension. 2011; 7 (3): 12–7. [in Russian]
12. Morozova T.E. Sartany v lechenii bol'nykh arterial'noi gipertenziei vysokogo riska: vozmozhnosti kandesartana. Systemic Hypertension. 2013; 9 (2): 34–9. [in Russian]
13. Giliarevskii S.R., Golshmid M.V., Kuz'mina I.M. Dokazatel'naia istoriia kandesartana: proshloe, budushchee i nastoiashchee. Serdechnaia nedostatochnost'. 2015; 16 (5): 303–10. [in Russian]
14. Oparll S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens 2000; 13 (1 Pt 2): 188–248.
15. Evdokimova A.G., Lozhkina M.V., Kovalenko E.V. Key features of candesartan application in clinical practice. Consilium Medicum. 2016; 18 (1): 54–9. [in Russian]
16. Le MT, De Bakcer JP, Hanyady L et al. Ligand binding and functional properties of human angiotensin AT I receptors in transiently and stably expressed CHO-K1 cell. Eur J Pharmacol 2005; 513 (1–2): 35–45.
17. Ostroumova O.D., Bondarets O.V., Guseva T.F. The benefits of candesartan usage in the treatment of arterial hypertension. Systemic Hypertension. 2014; 10 (2): 62–6. [in Russian]
18. Lee HY, Hong BK, Chung WJ et al. Phase IV, 8-week, multicenteral, randomized, active treatment-controlled, parallel grope, efficacy and tolerability of candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension. Clin Ther 2011; 33 (8): 1043–56.
19. Easthope SE, Jarvis B. Candesartan cilexetil in update of its use in essential hypertension. Drugs 2002; 62: 1253–87.
20. Vidi DG, While WB, Ridley E et al and the CLAIM Study Investigators. A forsed titration study of antihypertensive efficacy of candesartanin cilexetil in comparison to losartan. CLAIM Study II. J Hum Hypertens 2001; 15: 475–80.
21. Hasegawa H, Takano H, Kameda E et al. Effect of switching from telmisartan, valsartan, olmesartan or losartan, to candesartan on morning hypertension. Clin Exp Hypertens 2012; 34 (2): 86–91.
22. Minatoquchi S, Aoyama T, Kawai N et al. Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. Blood Press 2013; 22.
23. Ogihara T, Fujimoto A, Nakao K, Saruta T. CASE-J Trial Group. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Exp Rev Cardiovasc Ther 2008; 6 (9): 1195–201.
24. Ogihara T, Nakao K, Fukui T et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008; 51 (2): 393–8.
25. Penicka M, Gregor P, Kerekes R et al. Candesartan use in Hypertrophic And Non-obstructive Cardiomyopathy Estate (CHANCE) Study. The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. J Mol Diagn 2009; 11: 35–41.
26. Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363–9.
27. Kurata A, Nishizawa H, Kihara S et al. Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 2006; 70: 1717–24.
28. Rudziftski W, Swiat M, Tomaszewski M et al. Cerebral hemodynamics and investigations of cerebral blood flow regulation. Nucl Med Rev Cent East Eur 2007; 10: 29–42.
29. Lithell H, Hansson L, Skoog I et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–86.
30. Schrader J, Kulschewski A et al. Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34: 1699–703.
31. Kasanuki H, Hagiwara N, Hosoda S et al. Angiotensin II receptor blocker-based vs non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30 (10): 1203–12.
32. Burnier M. Managing 'resistance': is adherence a target for treatment? Curr Opin Nephrol Hypertens 2014; 23 (5): 439–43.
33. Fliser D, Wagner K, Loss A et al. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16: 1135–40.
34. De Rosa ML. Cardio classics revisited – focus on the role of candesartan. Vas Health Risk Management 2010; 6: 1047–63.
35. Pfeffer MA, Swedberg K, Granger CB et al. For the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759–66.
36. Granger CB, McMurray JJV, Yusuf S et al. For the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin converting enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772–6.
37. McMurray JJV, Оstergren J, Swedberg K et al. For the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin converting enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767–71.
38. Yusuf S, Pfeffer MA, Swedberg K et al for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777–81.
39. Chazova I.E., Ratova L.G. Pervoe pokolenie sartanov: est' li perspektivy. Systemic Hypertension. 2010; 4: 3–7. [in Russian]
40. Ducharme A, Swedberg K, Pfeffer MA et al. CHARM Investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152: 86–92.
41. Dobrynina N.V. What we know about candesartan: clinical applications. Consilium Medicum. 2016; 18 (5): 64–6. [in Russian]
Авторы
С.А.Бернс*, Р.И.Стрюк
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1
*svberns@yandex.ru
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
*svberns@yandex.ru
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1
*svberns@yandex.ru
________________________________________________
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
*svberns@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.